Efficacy and safety of bazedoxifene for postmenopausal osteoporosis

References

• RaiszLGPathogenesis of osteoporosis: concepts, conflicts, and prospectsJ Clin Invest2005115123318332516322775
   PubMed Web of Science ®Google Scholar
• SambrookPCooperCOsteoporosisLancet200636795272010201816782492
   PubMed Web of Science ®Google Scholar
• CauleyJAThompsonDEEnsrudKCScottJCRisk of mortality following clinical fracturesOsteoporos Int200011755656111069188
   PubMed Web of Science ®Google Scholar
• BianchiMLOrsiniMRSaraifogerSOrtolaniSRadaelliGBettiSQuality of life in post-menopausal osteoporosisHealth Qual Life Outcomes200537816321148
   PubMedGoogle Scholar
• SirisESBrennemanSKBarrett-ConnorEThe effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99 results from the National Osteoporosis Risk Assessment (NORA)Osteoporos Int200617456557416392027
   PubMed Web of Science ®Google Scholar
• LewieckiEMCurrent and emerging pharmacologic therapies for the management of postmenopausal osteoporosisJ Womens Health2009181016151626
   Web of Science ®Google Scholar
• CauleyJASeeleyDGEnsrudKEttingerBBlackDCummingsSREstrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research GroupAnn Intern Med199512219167985914
   PubMed Web of Science ®Google Scholar
• MichaëlssonKBaronJAJohnellOPerssonILjunghallSVariation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture Study GroupOsteoporos Int19988654054610326058
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLPrenticeRLWriting Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trialJAMA2002288332132312117397
   PubMed Web of Science ®Google Scholar
• CuzickJBaumMTamoxifen and contralateral breast cancerLancet1985284492822862460
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJRedmondCA randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumorsN Engl J Med198932084794842644532
   PubMed Web of Science ®Google Scholar
• LoveRRMazessRBBardenHSEffects of tamoxifen on bone mineral density in postmenopausal women with breast cancerN Engl J Med1992326138528561542321
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPRedmondCKFisherERWickerhamDLCroninWMEndometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14J Natl Cancer Inst19948675275378133536
   PubMed Web of Science ®Google Scholar
• BlackLJSatoMRowleyERRaloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized ratsJ Clin Invest199493163698282823
   PubMed Web of Science ®Google Scholar
• EttingerBBlackDMMitlakBHReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA1999282763764510517716
   PubMed Web of Science ®Google Scholar
• DelmasPDEnsrudKEAdachiJDMulitple Outcomes of Raloxifene Evaluation InvestigatorsEfficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialJ Clin Endocrinol Metab20028783609361712161484
   PubMed Web of Science ®Google Scholar
• GruberCGruberDBazedoxifene (Wyeth)Curr Opin Investig Drugs200451010861093
   PubMedGoogle Scholar
• GennariLMerlottiDDe PaolaVMartiniGNutiRBazedoxifene for the prevention of postmenopausal osteoporosisTher Clin Risk Manag2008461229124219337430
   PubMedGoogle Scholar
• MillerCPColliniMDTranBDDesign, synthesis, and preclinical characterization of novel, highly selective indole estrogensJ Med Chem200144111654165711356100
   PubMed Web of Science ®Google Scholar
• KommBSLyttleCRDeveloping a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluationAnn N Y Acad Sci200194931732611795370
   PubMed Web of Science ®Google Scholar
• KommBSKharodeYPBodinePVHarrisHAMillerCPLyttleCRBazedoxifene acetate: a selective estrogen receptor modulator with improved selectivityEndocrinology200514693999400815961563
   PubMed Web of Science ®Google Scholar
• PeanoBJCrabtreeJSKommBSWinnekerRCHarrisHAEffects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary glandEndocrinol2009150418971903
   PubMed Web of Science ®Google Scholar
• ErmerJMcKeandWSullivanPBazedoxifene acetate dose proportionality in healthy, postmenopausal womenClin Pharmacol Ther200373246
   Web of Science ®Google Scholar
• ChandrasekaranAMcKeandWESullivanPDeMaioWStoltzRScatinaJMetabolic disposition of [14C]bazedoxifene in healthy postmenopausal womenDrug Metab Dispos20093761219122519273530
   PubMed Web of Science ®Google Scholar
• RonkinSClarkeLTSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashionJ Bone Miner Res200116Suppl 1S413
   Google Scholar
• RonkinSNorthingtonRBaracatEEndometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal womenObstet Gynecol200510561397140415932835
   PubMed Web of Science ®Google Scholar
• BoudesPRonkinSKornerSEffects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast painOsteoporos Int200314Suppl 7S14
   Google Scholar
• MillerPDChinesAAChristiansenCEffects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled studyJ Bone Miner Res200823452553518072873
   PubMed Web of Science ®Google Scholar
• SilvermanSLChristiansenCGenantHKEfficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trialJ Bone Miner Res200823121923193418665787
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellOOdenAJohanssonHMcCloskeyEFRAX and the assessment of fracture probability in men and women from the UKOsteoporos Int200819438539718292978
   PubMed Web of Science ®Google Scholar
• KanisJAJohanssonHOdenAMcCloskeyEVBazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAXBone20094461049105419254788
   PubMed Web of Science ®Google Scholar
• de VilliersTJBazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosisClimacteric201013321021820184423
   PubMed Web of Science ®Google Scholar
• PinkertonJVArcherDFUtianWHBazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosisMenopause20091661102110819546825
   PubMed Web of Science ®Google Scholar
• ArcherDFPinkertonJVUtianWHBazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal womenMenopause20091661109111519543129
   PubMed Web of Science ®Google Scholar
• HarveyJAHolmMKRanganathRGusePATrottEAHelznerEThe effects of bazedozifene on mammographic breast density in postmenopausal women with osteoporosisMenopause20091661193119619503006
   PubMed Web of Science ®Google Scholar
• de VilliersTJChinesAAPalaciosSSafety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trialOsteoporos Int201122256757620535606
   PubMed Web of Science ®Google Scholar
• KharodeYBodinePVMillerCPLyttleCRKommBSThe pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis preventionEndocrinology2008149126084609118703623
   PubMed Web of Science ®Google Scholar
• PeanoBJCrabtreeJSKommBSWinnekerRCHarrisHAEffects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary glandEndocrinology200915041897190319022889
   PubMed Web of Science ®Google Scholar
• PickarJHYehITBachmannGSperoffLEndometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapyFertil Steril20099231018102419635613
   PubMed Web of Science ®Google Scholar
• LoboRAPinkertonJVGassMLEvaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profileFertil Steril20099231025103819635615
   PubMed Web of Science ®Google Scholar
• ArcherDFLewisVCarrBROlivierSPickarJHBazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal womenFertil Steril20099231039104419635614
   PubMed Web of Science ®Google Scholar
• LindsayRGallagherJCKaganRPickarJHConstantineGEfficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal womenFertil Steril20099231045105219635616
   PubMed Web of Science ®Google Scholar
• LindsayRPreventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE)Osteoporos Int201122244745121069294
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• FavusMJBisphosphonates for osteoporosisN Engl J Med2011363212027203521083387
   PubMed Web of Science ®Google Scholar
• PapapetrouPDBisphosphonate-associated adverse eventsHormones2009829611019570737
   PubMedGoogle Scholar
• KennelKADrakeMTAdverse effects of bisphosphonates: implications for osteoporosis managementMayo Clin Proc200984763263819567717
   PubMed Web of Science ®Google Scholar
• RuggieroSLMehrotraBBisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and managementAnnu Rev Med200960859618928335
   PubMed Web of Science ®Google Scholar
• KawaiMMödderUIKhoslaSRosenCJEmerging therapeutic opportunities for skeletal restorationNat Rev Drug Discov201110214115621283108
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• BodyJJGaichGAScheeleWHA randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosisJ Clin Endocrinol Metab200287104528453512364430
   PubMed Web of Science ®Google Scholar
• HodsmanABBauerDCDempsterDWParathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useEndocr Rev200526568870315769903
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorEMoscaLCollinsPRaloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenN Engl J Med2006355212513716837676
   PubMed Web of Science ®Google Scholar
• VogelVGCostantinoJPWickerhamDLNational Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialJAMA2006295232727274116754727
   PubMed Web of Science ®Google Scholar
• BushardtRLTurnerJLRagucciKRAskinsDGJrNon-estrogen treatments for osteoporosis: an evidence-based reviewJAAPA20061912253017243258
   PubMedGoogle Scholar
• ParaciosSEfficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosisCurr Med Res Opin20102671553156320429824
   PubMed Web of Science ®Google Scholar